Individualized glycaemic targets and pharmacotherapy in type 2 diabetes

Diabetes and Vascular Disease Research

Volumn 10, Issue 5, 2013, Pages 397-409

  Bailey, Clifford J ^a   Aschner, Pablo ^b   Del Prato, Stefano ^c   LaSalle, James ^d   Ji, Linong ^e   Matthaei, Stephan ^f  

^a ASTON UNIVERSITY   (United Kingdom)

^b PONTIFICIA UNIVERSIDAD JAVERIANA   (Colombia)

^c UNIVERSITY OF PISA   (Italy)

^d Medical Arts Research Collaborative   (United States)

^e PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^f Diabetes Zentrum Quakenbruck   (Germany)

Author keywords

Global Partnership; Glycaemic targets; HbA1c; individualized therapy; type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; BROMOCRIPTINE; COLESEVELAM; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLICLAZIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; INDAPAMIDE PLUS PERINDOPRIL; INSULIN DERIVATIVE; METFORMIN; PRAMLINTIDE; SODIUM GLUCOSE COTRANSPORTER 2; SULFONYLUREA;

CARDIOVASCULAR RISK; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE COURSE; DRUG SAFETY; DRUG TARGETING; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEALTH CARE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN RESISTANCE; LACTIC ACIDOSIS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PREGNANCY; PUBLICATION; REVIEW; SELF CARE; TREATMENT OUTCOME;

GLOBAL PARTNERSHIP; GLYCAEMIC TARGETS; HBA1C; INDIVIDUALIZED THERAPY; TYPE 2 DIABETES;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INDIVIDUALIZED MEDICINE; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME;

EID: 84882323601     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164113490765     Document Type: Review

References (43)

1. Del Prato S, Felton AM, Munro N, et al. Improving glucose management: ten steps to get more patients with type 2 diabetes to glycaemic goal. Int J Clin Pract. 2005 ; 59: 1345-1355
2. Bennett WL, Odelola OA, Wilson LM, et al. Evaluation of guideline recommendations on oral medications for type 2 diabetes mellitus: a systematic review. Ann Intern Med. 2012 ; 156: 27-36
3. Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med. 2007 ; 147: 386-399
4. Bennett WL, Maruthur NM, Singh S, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med. 2011 ; 154: 602-613
5. Mann DM, Woodward M, Ye F, et al. Trends in medication use among US adults with diabetes mellitus: glycemic control at the expense of controlling cardiovascular risk factors. Arch Intern Med. 2009 ; 169: 1718-1720
6. Miccoli R, Penno G, Del Prato S. Multidrug treatment of type 2 diabetes: a challenge for compliance. Diabetes Care. 2011 ; 34: 231-235
7. Del Prato S, LaSalle J, Matthaei S, et al. Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Partnership for Effective Diabetes Management. Int J Clin Pract. 2010 ; 64: 295-304
8. Nathan DM, Buse JB, Davidson MB, et al. The American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009 ; 32: 193-203
9. Standards of medical care in diabetes - 2012. Diabetes Care. 2012 ; 35: 11-63
10. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998 ; 352: 837-853
11. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008 ; 359: 1577-1589
12. Aschner PJ, Ruiz AJ. Metabolic memory for vascular disease in diabetes. Diabetes Technol Ther. 2012 ; 14: 68-74
13. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008 ; 358: 2545-2559
14. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008 ; 358: 2560-2572
15. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009 ; 360: 129-139
16. Bailey CJ, Blonde L, Del Prato S, et al. What are the practical implications for treating diabetes in light of recent evidence? Updated recommendations from the Global Partnership for Effective Diabetes Management. Diab Vasc Dis Res. 2009 ; 6: 283-287
17. Ray KK, Seshasai SRK, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009 ; 373: 1765-1772
18. Hemmingsen B, Lund SS, Gluud C, et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2011 ;:
19. Mannucci E, Monami M, Lamanna C, et al. Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2009 ; 19: 604-612
20. Turnbull FM, Abraira C, Anderson RJ, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009 ; 52: 2288-2298
21. Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ. 2010 ; 340: b4909
22. Riddle MC, Ambrosius WT, Brillon DJ, et al. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care. 2010 ; 33: 983-990
23. Zoungas S, Patel A, Chalmers J, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010 ; 363: 1410-1418
24. Pozzilli P, Leslie RD, Chan J, et al. The A1C and ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach. Diabetes Metab Res Rev. 2010 ; 26: 239-244
25. Brunetti P. The lean patient with type 2 diabetes: characteristics and therapy challenge. Int J Clin Pract Suppl. 2007 ; 153: 3-9
26. Sinharoy K, Mandal L, Chakrabarti S, et al. A study on clinical and biochemical profile of low body weight type 2 diabetes mellitus. J Indian Med Assoc. 2008 ; 106: 747-750
27. Flint A, Arslanian S. Treatment of type 2 diabetes in youth. Diabetes Care. 2011 ; 34: S177 - S183
28. Zeitler P, Hirst K, Pyle L, et al. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med. 2012 ; 366: 2247-2256
29. Bakris GL. Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus. Mayo Clin Proc. 2011 ; 86: 444-456
30. Type 2 diabetes: the management of type 2 diabetes. CG87. London: National Institute for Health and Clinical Excellence ; 2009 :
31. Bailey CJ, Kodack M. Patient adherence to medication requirements for therapy of type 2 diabetes. Int J Clin Pract. 2011 ; 65: 314-322
32. Frye RL, August P, Brooks MM, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009 ; 360: 2503-2515
33. Ismail-Beigi F, Moghissi E, Tiktin M, et al. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med. 2011 ; 154: 554-559
34. Del Prato S. Megatrials in type 2 diabetes. From excitement to frustration?. Diabetologia. 2009 ; 52: 1219-1226
35. Frier BM, Schernthaner G, Heller SR. Hypoglycemia and cardiovascular risks. Diabetes Care. 2011 ; 34: S132 - S137
36. Yakubovich N, Gerstein HC. Serious cardiovascular outcomes in diabetes: the role of hypoglycemia. Circulation. 2011 ; 123: 342-348
37. Tieu J, Coat S, Hague W, et al. Oral anti-diabetic agents for women with pre-existing diabetes mellitus/impaired glucose tolerance or previous gestational diabetes mellitus. Cochrane Database Syst Rev. 2010 ; 10: CD007724
38. Leguizamon G, Igarzabal ML, Reece EA. Periconceptional care of women with diabetes mellitus. Obstet Gynecol Clin North Am. 2007 ; 34: 225-239
39. Sheth B. Does pregnancy accelerate the rate of progression of diabetic retinopathy?. Curr Diab Rep. 2002 ; 23: 327-330
40. Rowan JA, Hague WM, Gao W, et al. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med. 2008 ; 358: 2003-2015
41. Standards of medical care in diabetes - 2010. Diabetes Care. 2010 ; 33: S11 - S61
42. Salpeter S, Greyber E, Pasternak G, et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus (review). Cochrane Database Syst Rev. 2006 ; 1: CD002967
43. Bailey CJ. Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol Sci. 2011 ; 32: 63-71